Tenvir-EM Tablets

Tenvir-EM is a highly trusted, fixed-dose combination antiretroviral medication manufactured by Cipla. Each tablet combines two powerful nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs): Emtricitabine ($200\text{ mg}$) and Tenofovir Disoproxil Fumarate ($300\text{ mg}$). It is clinically indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, and it is widely utilized in pre-exposure prophylaxis (PrEP) regimens to reduce the risk of sexually acquired HIV-1 in high-risk individuals. Designed for convenient once-daily oral administration, Tenvir-EM effectively blocks viral replication, helping healthcare providers achieve robust viral suppression and optimize long-term patient outcomes.